Betapace AF Education Will Emphasize Use Only For Severe Symptoms
Berlex' Betapace AF educational program should emphasize use only in highly symptomatic patients, FDA said in its Feb. 22 approval letter for sotalol for atrial fibrillation and atrial flutter.
You may also be interested in...
Berlex' Betapace indication for atrial fibrillation patients should include language emphasizing the anti-arrhythmic's intended use in patients in normal sinus rhythm rather than for conversion from atrial fibrillation or flutter, FDA's Cardio-Renal Drugs Advisory Committee members told the agency April 29.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials